...show a resurgence in recalls related to application integrity issues. Potency problems continue to be the source of a high percentage of recalls. Overall, the number and types of drug product recalls reported in 1997 are in line with the 1996 tally. Labeling/packaging recalls are an exception, more than doubling from the prior year. Comments on a proposed cGMP rule modifying the cut labeling provisions are under review at FDA. Recalls of injectables also spike in 1997. FDA considers four drug recalls involving various dosage forms and one therapeutic biological recall dangerous enough to warrant a Class I rating. [A nine-page tabulation of recalls listed in FDA "Enforcement Reports" during 1997 is included.]
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Only Bausch Health’s Xifaxan may have had a lower initial offer among the 15 drugs in the current Medicare price negotiation round, researchers at the University of Washington and the University of California, San Diego, projected.
Sponsors should consider whether their TV commercials contain the same number of scene changes during the major statement as ads that received a violation letter.
One clear message from a US FDA listening session on leveraging knowledge across cell and gene therapy products is sponsors want more guidance on how the FDA’s new platform therapy pathway will function.
